ACG Clinical Guideline: Primary Sclerosing Cholangitis

Area of Science:

• Hepatology
• Gastroenterology
• Autoimmune Diseases

Background:

• Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease characterized by bile duct inflammation and fibrosis.
• PSC is associated with an increased risk of cholangiocarcinoma and colorectal cancer.
• The etiology of PSC remains largely unknown, but it frequently co-occurs with inflammatory bowel disease, particularly ulcerative colitis.

Purpose of the Study:

• To summarize the current understanding of primary sclerosing cholangitis.
• To highlight the clinical manifestations, complications, and management challenges of PSC.
• To underscore the unmet need for effective therapies for PSC.

Main Methods:

• Literature review of primary sclerosing cholangitis.
• Synthesis of information on epidemiology, pathogenesis, clinical features, and treatment of PSC.
• Analysis of complications and long-term outcomes in PSC patients.

Main Results:

• PSC is a rare but severe cholestatic liver disease with significant morbidity and mortality.
• Current management is largely supportive, with ursodeoxycholic acid used empirically.
• Complications include portal hypertension, vitamin deficiencies, bone disease, and increased cancer risk.

Conclusions:

• Primary sclerosing cholangitis is a challenging disease with a significant impact on patient survival.
• There are no approved therapies, and management focuses on symptom control and complication prevention.
• Further research into PSC pathogenesis and novel therapeutic strategies is urgently needed.